A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 29277795
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in
      Patients Treated with Tyrosine Kinase Inhibitors.
PG  - 359-365
AB  - AIM: The study aimed to define the true impact of pancreatic metastases (PM) from
      renal cell carcinoma on overall survival (OS) in patients treated with first-line
      tyrosine kinase inhibitors. PATIENTS AND METHODS: Overall, 321 consecutive
      patients were analysed. The influence of PM on OS was assessed using the
      Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two
      multivariabe Cox proportional hazards regressions (CPHR). RESULTS: Thirty-four
      patients (10%) had PM and 287 (90%) had sites of metastasis other than the
      pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted
      log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant 
      factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66,
      p=0.098). CONCLUSION: The presence of PM was not an independent prognostic
      factor, but was rather an indicator of an indolent course of the disease.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chrom, Pawel
AU  - Chrom P
AD  - Department of Oncology, Military Institute of Medicine, Warsaw, Poland
      [email protected]
FAU - Stec, Rafal
AU  - Stec R
AD  - Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
FAU - Bodnar, Lubomir
AU  - Bodnar L
AD  - Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
FAU - Szczylik, Cezary
AU  - Szczylik C
AD  - Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC (Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Renal Cell/*pathology/surgery
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*mortality/*secondary
MH  - Prognosis
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Retrospective Studies
MH  - Survival Analysis
OT  - *Metastatic renal cell carcinoma
OT  - *overall survival
OT  - *pancreatic metastases
OT  - *prognostic factor
OT  - *tyrosine kinase inhibitor
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/02 00:00 [received]
PHST- 2017/10/21 00:00 [revised]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/359 [pii]
AID - 10.21873/anticanres.12230 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):359-365. doi: 10.21873/anticanres.12230.